Investors are suing Boston Beer Co. for misrepresenting the sales performance of its seltzer product line, which includes Angry Orchard Hard Seltzer and Truly Hard Seltzer.
At least three law firms have sued Boston Beer.
The number of lawsuits is expected to increase as law firms are now searching for potential plaintiffs to represent among Boston Beer’s investors.
Among the law firms was Robbins Geller Rudman & Dowd LLP, which said that management’s positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
The seltzer products performed below expectations in the quarter ending in June, prompting management to revise its sales forecast in July.
Consequently, the share price of Boston Beer stock plunged 26 percent and has continued to decline and is now down about 60 percent from its peak in April.
It now stands at $526 a share.


U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Norway Opens Corruption Probe Into Former PM and Nobel Committee Chair Thorbjoern Jagland Over Epstein Links
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive
Jerome Powell Attends Supreme Court Hearing on Trump Effort to Fire Fed Governor, Calling It Historic
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
New York Judge Orders Redrawing of GOP-Held Congressional District
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



